Navigation Links
MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices
Date:9/7/2011

SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- MedWaves' AveCure™ microwave coagulation-ablation (MWA) system uses microwave energy to volumetrically coagulate-ablate (destroy) soft-tissue lesions (abnormal structures) safely, effectively, precisely and with repeatability. The system has successfully treated over one-thousand patients worldwide, including lesions in bone, kidney, liver, lung and pancreas. The Company plans to bring its technology to treat lesions in other locations in the body. The Company's technology makes available treatment options for many cancer patients in either early or late stage and helps those who are running out of options.

People's Republic of China, with over 1.3 billion in population, is an important market for MedWaves. Every year, 2.6 million Chinese people are diagnosed with cancer, and 1.8 million deaths result from it. Cancer became the number-one cause of death among all illnesses in China in 2009. Lung and liver cancers are the leading cause of cancer deaths in China, and the Company is pleased to receive SFDA approval to import and sell its products to help those in need. MedWaves will work in close coordination with its Chinese distributor-partners to schedule and conduct clinical evaluations for the sale of its AveCure™ system in key hospitals in China. Earlier this year, Hong Kong University published its successful treatment of tumors in the liver using the MedWaves AveCure™ microwave ablation system. The Hong Kong University has adopted MedWaves™ Avecure system as a cancer treatment tool.

About AveCure™ Microwave Coagulation-Ablation System and Devices:

MedWaves AveCure™ Microwave Coagulation-Ablation System overcomes the limitations of other microwave and radiofrequency (RF) thermal ablation technologies to destroy lesions safely, effectively, precisely and with repeatability and uniformity. It is the only system approved in the market to provide clinicians with patented fully integrated real-time temperature, both forward and reverse-power feedback to control energy delivery intelligently. The system, which consists of a generator, extension cable set, and an array of single-patient-use microwave-probe devices, enables the surgeons and interventional radiologists to treat soft-tissue lesions, such as tumors, safely and easily, with confidence. This single-patient-use device provides a continuous revenue stream. MedWaves AveCure™ Microwave Coagulation-Ablation System has also received USFDA approval for sales in the United States and CE mark for sales in Europe. Other received approval and certification announcements to follow.

About MedWaves, Incorporated

MedWaves, Inc., a United States company based in San Diego, California, develops innovative and proprietary microwave ablation technology for the minimally invasive coagulation-ablation products for soft tissue lesions, such as tumors. The Company's management team has extensive experience in the medical device marketplace. The Company's proprietary technology allows for the development of minimally invasive microwave antenna devices in a wide range of sizes, shapes and flexibility to meet the clinicians' requirements in the treatment of lesions in bone, kidney, liver, lung, pancreas and other locations in the body.

Contact Information:

Theodore Ormsby (email: tedormsby@avecure.com)
Mobile: 858-342-3331

George Leung, PhD (email: gleung@avecure.com)
Mobile: 858-705-5056

16760 W Bernardo Drive, San Diego, CA 92127, Tel: 858-946-0015, Website: http://www.medwaves.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE MedWaves, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO
2. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
3. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
4. Accuray Incorporateds CEO to Speak at 27th Annual JP Morgan Healthcare Conference
5. Accuray Incorporated to Report Second Quarter Fiscal Year 2009 Financial Results
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViewRay Incorporated Closes $15M Tranche of Series B Financing and Announces Partnership with Siemens AG
8. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. Spherix Incorporated to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... AUSTIN, Texas, March 29, 2017  Vermillion, Inc. ... gynecologic disease, reported on its results for the ... 2016. "2016 marked a pivotal year ... ACOG guideline inclusion, international distribution agreements, major reimbursement ... in network payer agreements. In addition we cleared ...
(Date:3/29/2017)... - Last year,s petition to the White House signed by ... to generate awareness on the importance of new organic medicines and ... market place. ... Earlier this month Health Advance (OTC PINK: HADV ... products, announced its endeavors on this generally recognized as safe ...
(Date:3/29/2017)... ... March 29, 2017 , ... (March ... International Mexico has been approved as an active member of the Mexican ... protection among distributers and consumers in relationship marketing. This professional organization fosters loyal ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
Breaking Biology Technology:
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
Breaking Biology News(10 mins):